FAIR VALUE DISCLOSURES - Acquired (Details)			3 Months Ended		6 Months Ended
	May 25, 2023 USD ($)	Jul. 21, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Intangible asset impairment charge			$ 0	$ 112,000	$ 0	$ 112,000
Finite-lived intangible gross carrying amount			485,244,000		485,244,000		$ 480,915,000
Research and development			7,374,000	$ 4,165,000	13,298,000	$ 9,439,000
Acquired ANDAs intangible assets
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Finite-lived intangible gross carrying amount			200,191,000		200,191,000		$ 195,862,000
Akorn Holding Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Total asset purchase	$ 4,800,000
Akorn Holding Company | Acquired ANDAs intangible assets
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Intangible assets acquired	$ 4,300,000
Oakrum Pharma | Acquired ANDAs intangible assets
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Total asset purchase		$ 8,000,000
Intangible asset impairment charge			$ 0		0
Finite-lived intangible gross carrying amount		7,200,000
Research and development		$ 1,200,000
Contingent liability not recognized, asset acquisition					$ 200,000
Useful life of intangible assets		7 years
Oakrum Pharma | Acquired ANDAs intangible assets | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Intangible asset measurement input		13